Hyperlipidemia and Statins Use for the Risk of New Diagnosed Sarcopenia in Patients with Chronic Kidney: A Population-Based Study

Abstract

Background: Previous research found that statins, in addition to its efficiency in treating hyperlipidemia, may also incur adverse drug reactions, which mainly include myopathies and abnormalities in liver function. Aim: This study aims to assess the risk for newly onset sarcopenia among patients with chronic kidney disease using statins. Material and Method: In a nationwide retrospective population-based cohort study, 75,637 clinically confirmed cases of chronic kidney disease between 1997 and 2011were selected from the National Health Insurance Research Database of Taiwan. The selection of the chronic kidney disease cohort included a discharge diagnosis with chronic kidney disease or more than 3 outpatient visits with the diagnosis of chronic kidney disease found within 1 year. After consideration of patient exclusions, we finally got a total number of 67,001 cases of chronic kidney disease in the study. The Cox proportional hazards model was used to perform preliminary analysis on the effect of statins usage on the occurrence of newly diagnosed sarcopenia; the Cox proportional hazards model with time-dependent covariates was conducted to take into consideration the individual temporal differences in medication usage, and calculated the hazard ratio (HR) and 95% confidence interval after controlling for gender, age, income, and urbanization. Results: Our main findings indicated that patients with chronic kidney disease who use statins seem to effectively prevent patients from occurrences of sarcopenia, high dosage of statins seem to show more significant protective effects, and the results are similar over long-term follow-up. In addition, the risk for newly diagnosed sarcopenia among patients with lipophilic statins treatment was lower than that among patients with hydrophilic statins treatment. Conclusion: It seems that patients with chronic kidney disease could receive statin treatment to reduce the occurrence of newly diagnosed sarcopenia. Additionally, a higher dosage of statins could reduce the incidence of newly diagnosed sarcopenia in patients with chronic kidney disease.

Acute sarcopenia changes following hospitalization: influence of pre-admission care dependency level

“…It is also plausible that dependent older people living at home have different nutritional status and/or gut microbial profile compared to those who are independently living or living in care homesthere is considerable evidence that nutritional status as well as the gut microbial composition influences muscle status in older people [29][30][31]. Also, the medication profile would be an interesting covariate, as chronic drugs such as ACEinhibitors and statins have shown to affect muscle-related outcomes in older people [32,33]. It could also be that the medical attention and drug monitoring before or in hospital in the three investigated groups differed.…”

Angiotensin II receptor blocker and statin combination therapy associated with higher skeletal muscle index in patients with cardiovascular disease: A retrospective study

“…7 Riechman et al 8 reported that statins are associated with an increased lean mass following resistance training in community-dwelling elderly adults. Recently, Lin et al 11 demonstrated that statin treatment reduces the occurrence of newly diagnosed sarcopenia in patients with chronic kidney disease. Additionally, ARB use has been reported to be associated with preserved skeletal muscle strength in chronic haemodialysis patients.…”

Enhanced Risk of Osteoporotic Fracture in Patients with Sarcopenia: A National Population-Based Study in Taiwan

“…In other words, there is no specific disease code for sarcopenia in our population-based data collected from Taiwan’s NHIRD, in which ICD-9-CM was the main disease coding system before 2020. However, this study utilized the ICD-9-CM code 728.2 (muscular wasting and disuse atrophy, not elsewhere classified) as the representative code, with strict selection criteria for the main diagnostic coding and number of outpatient visits or hospitalization; this was important in order to identify the potential patients with sarcopenia and minimize coding errors or interference from similar or coexisting diseases, acting in concert with the same methods used in the previously published population-based study [ 14 , 15 ]. The evidence from this study should have high reliability because of the large number of patients and long follow-up time to assess the influence of sarcopenia on fracture risk.…”